Jovanovic, Ana
Klassen, Philipp
Heuschmann, Peter
Sommer, Claudia
Roberts, Mark
Üçeyler, Nurcan
Funding for this research was provided by:
Sanofi Genzyme
Deutsche Forschungsgemeinschaft (UE171/5-1)
Projekt DEAL
Article History
Received: 20 June 2020
Accepted: 13 October 2020
First Online: 20 October 2020
Ethics approval and consent to participate
: The NHS Research Ethics Committee approved our study REC Ref 18/NE/0010, IRAS ID 218876. All study participants gave written consent before inclusion.
: No individual person’s data is included in our manuscript.
: AJ: speaker honoraria, travel grants, and research grants: Sanofi Genzyme, Amicus and Takeda. PK: no competing interest. PH: reports research grants from German Ministry of Research and Education, German Research Foundation, European Union, Charité—Universitätsmedizin Berlin, Berlin Chamber of Physicians, German Parkinson Society, University Hospital Würzburg, Robert Koch Institute, German Heart Foundation, Federal Joint Committee (G-BA) within the Innovationfond, University Hospital Heidelberg (within RASUNOA-prime; supported by an unrestricted research grant to the University Hospital Heidelberg from Bayer, BMS, Boehringer-Ingelheim, Daiichi Sankyo), Charité—Universitätsmedizin Berlin (within Mondafis; supported by an unrestricted research grant to the Charité from Bayer), University Göttingen (within FIND-AF randomized; supported by an unrestricted research grant to the University Göttingen from Boehringer-Ingelheim), outside the submitted work. CS: speaker honoraria from Takeda and Sanofi. MR: speaker honoraria, travel grants,: Sanofi Genzyme, Amicus, and Takeda. NÜ: speaker honoraria, travel grants, and research grants: Sanofi Genzyme, Takeda, Idorsia.